Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ScandiDos ABFRA:2FV -3.06%47 Equity-to-Asset is 0.63 as of Apr. 2026, which is 5% above its 10-year median of 0.60. GuruFocus rates FRA:2FV with a GF Score™ of 47/100 and a GF Value™ of €0.06. The stock has 4 warning signs investors should review. Among 852 Medical Devices & Instruments companies, ScandiDos AB ranks better than 50.12% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. ScandiDos AB's Total Stockholders Equity for the quarter that ended in Apr. 2026 was €3.84 Mil. ScandiDos AB's Total Assets for the quarter that ended in Apr. 2026 was €6.09 Mil.
Therefore, ScandiDos AB's Equity to Asset Ratio for the quarter that ended in Apr. 2026 was 0.63.
The historical rank and industry rank for ScandiDos AB's Equity-to-Asset or its related term are showing as below:
FRA:2FV'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41 Med: 0.6 Max: 0.7
Current: 0.63
During the past 13 years, the highest Equity to Asset Ratio of ScandiDos AB was 0.70. The lowest was 0.41. And the median was 0.60.
FRA:2FV's Equity-to-Asset is ranked better than 50.12% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.63
vs FRA:2FV: 0.63
ScandiDos AB (FRA:2FV) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
ScandiDos AB Equity-to-Asset Related Terms
ScandiDos AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for ScandiDos AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2FV vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, ScandiDos AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ScandiDos AB Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ScandiDos AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where ScandiDos AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
ScandiDos AB's Equity to Asset Ratio for the fiscal year that ended in Apr. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ScandiDos AB (FRA:2FV) has a Equity-to-Asset of 0.63 as of Apr. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on ScandiDos AB and its competitors. This is near median its historical median of 0.60. Over the past decade, ScandiDos AB's Equity-to-Asset has ranged from 0.41 to 0.70. According to the industry distribution chart, ScandiDos AB ranks #425 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 49.9%.
Is ScandiDos AB's Equity-to-Asset too high?
ScandiDos AB's current Equity-to-Asset of 0.63 is near median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 0.70. The Medical Devices & Instruments industry median Equity-to-Asset is 0.63. ScandiDos AB's value of 0.63 is 0% at this industry median. Based on the distribution chart, ScandiDos AB ranks #425 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ScandiDos AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does ScandiDos AB's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ScandiDos AB ranks #425 out of 852 companies for Equity-to-Asset. This puts ScandiDos AB in the upper half of its industry. The industry median Equity-to-Asset is 0.63. ScandiDos AB's value of 0.63 is 0% at this benchmark. Historically, ScandiDos AB's own Equity-to-Asset has ranged from 0.41 to 0.70 over the past decade. While the company's 10-year median is 0.60 vs. the industry median of 0.63, ScandiDos AB has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.63, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ScandiDos AB's current Equity-to-Asset of 0.63 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on ScandiDos AB and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ScandiDos AB's current Equity-to-Asset is 0.63, which is near median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ScandiDos AB stock overvalued right now?
ScandiDos AB (FRA:2FV) has a current Equity-to-Asset of 0.63. The stock's GF Value™ is €0.06, compared to a current price of €0.05 — trading 20.8% below its estimated fair value. The current Equity-to-Asset is 0.63, which is near median its 10-year median of 0.60 and 0% at the Medical Devices & Instruments industry median of 0.63. ScandiDos AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For ScandiDos AB (FRA:2FV), the current Equity-to-Asset is 0.63 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ScandiDos AB (FRA:2FV) Overvalued in 2026?
Based on GuruFocus' analysis, ScandiDos AB stock appears to be undervalued.
The current stock price of €0.05 is trading 20.8% below its estimated GF Value™ of €0.06.
Key valuation signals for FRA:2FV:
Equity-to-Asset: 0.63 (near median its 10-year median of 0.60)
GF Value™: €0.06 vs. price of €0.05 (20.8% below fair value)
Industry Position: 0% at the Medical Devices & Instruments median (#425 of 852)
No single metric tells the full story. See the FRA:2FV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ScandiDos AB is engaged in providing radiation therapy for cancer. Its product, Delta4 Phantom+, and its various hardware and software options are at the heart of everything ScandiDos does, from product development and production to marketing, sales, and customer support. With Delta4 HexaMotion ScandiDos has successfully developed a motion platform that recreates the movement of the tumor in six dimensions and independently simulates the patient's breathing movement.
47GF Score
Get the complete analysis for FRA:2FV
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2FV has been successfully added to your 
